Short drug test aims to see how breast tumors react
NCT ID NCT06710197
Summary
This study aimed to see if a 14-day course of an anti-inflammatory drug (Anakinra) could change the immune environment inside early-stage breast tumors before surgery. It planned to enroll patients with small, early triple-negative or ER-low breast cancers who were not getting chemotherapy first. The main goal was to measure changes in the tumor using tissue samples taken before and after the short drug treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE TRIPLE NEGATIVE ER LOW BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Health Network-Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.